Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 824-829

  Bai, Yu ^a   Wang, Yong Lian ^b   Yao, Wen Jian ^b   Guo, Ling ^b   Xi, Hui Fang ^b   Li, Song Yue ^b   Zhao, Bao Sheng ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b The Third Hospital of Xinxiang Medical University   (China)

Author keywords

MiR 32; Non small cell lung caner; Prognosis; Quantitative real time PCR

Indexed keywords

MICRORNA; MIRN32 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; DISEASE COURSE; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84923107007     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
2. Patz EF, Goodman PC and Bepler G. Screening for lung cancer. N Engl J Med 2000; 343: 1627-1633.
3. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP and Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355: 1763-1771.
4. Farazi TA, Spitzer JI, Morozov P and Tuschl T. miRNAs in human cancer. J Pathol 2011; 223: 102-115.
5. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6: 376-385.
6. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Zen K and Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
7. Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007; 26: 293-300.
8. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-1176.
9. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H and Beer DG. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009; 69: 5776-5783.
10. Xu JQ, Zhang WB, Wan R and Yang YQ. MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. Tumor Biol 2014; 35: 1-7.
11. Zhang J, Kuai X, Song M, Chen X, Yu Z, Zhang H and Mao Z. microRNA32 inhibits the proliferation and invasion of the SGC7901 gastric cancer cell line in vitro. Oncol Lett 2014; 7: 270-274.
12. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ and Teh BT. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009; 35: 109-114.
13. Jalava S, Urbanucci A, Latonen L, Waltering K, Sahu B, Jänne O, Seppälä J, Lähdesmäki H, Tammela T and Visakorpi T. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012; 31: 4460-4471.
14. Wu W, Yang J, Feng X, Wang H, Ye S, Yang P, Tan W, Wei G and Zhou Y. MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer 2013; 12: 30.
15. Edge SB and Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
16. Kim B, Lee HJ, Choi HY, Shin Y, Nam S, Seo G, Son DS, Jo J, Kim J and Lee J. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007; 67: 7431-7438.
17. Bartels CL and Tsongalis GJ. [MicroRNAs: novel biomarkers for human cancer]. Ann Biol Clin (Paris) 2010; 68: 263-272.
18. Tejero R, Navarro A, Campayo M, Viñolas N, Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L and Ramirez J. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One 2014; 9: e101899.
19. Li J, Li X, Ren S, Chen X, Zhang Y, Zhou F, Zhao M, Zhao C, Chen X and Cheng N. MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget 2014; 5: 7902.
20. Xu T, Liu X, Han L, Shen H, Liu L and Shu Y. Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clinical and Translational Oncology 2014; 16: 469-475.